0000000000368649

AUTHOR

Lourdes Chuliá-peris

showing 2 related works from this author

Interleukin-1β Modulation of the Mechanobiology of Primary Human Pulmonary Fibroblasts: Potential Implications in Lung Repair

2020

Pro-inflammatory cytokines like interleukin-1&beta

Male0301 basic medicinecollagenMMP2Interleukin-1betaMicroscopy Atomic Forcelcsh:ChemistryMechanobiologyCell MovementCitoquinespulmonary fibroblastsLunglcsh:QH301-705.5Col·lagenCells CulturedSpectroscopyChemistryGeneral MedicineBiomechanical PhenomenaComputer Science ApplicationsCell biologymedicine.anatomical_structureIL-1βCollagenaseCytokinesFemaleCollagenMMPsType I collagenmedicine.drugAdultAdolescentFilamentous actinArticleCollagen Type ICatalysisInorganic ChemistryContractilityYoung Adult03 medical and health sciencesDownregulation and upregulationcell mechanicsmedicineHumansRegenerationRNA MessengerPhysical and Theoretical ChemistryFibroblastMolecular BiologyCell ProliferationWound Healing030102 biochemistry & molecular biologyOrganic ChemistryFibroblastsActinsElasticityCollagen Type I alpha 1 ChainCollagen Type III030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Cyclooxygenase 2repairInternational Journal of Molecular Sciences
researchProduct

Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

2020

Abstract Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated radiographically, however, image-based evaluation of said therapies may not distinguish disease progression due to intrinsic tumor drug resistance or inefficient tumor penetration of the drugs. Here we report that the inhibition of mutated EGFR promotes the secretion of a potent vasoconstrictor, endothelin-1 (EDN1), which continues to increase as the cells become resistant with a mesenchymal phenotype. As EDN1 and its receptor (EDNR) is linked to cancer progression, EDNR-antagonists have been evaluated in several clinical trials with disappointing results. These trials were based on a hypothesis that…

Vascular Endothelial Growth Factor ACancer ResearchLung NeoplasmsAmbrisentanOncology and CarcinogenesisDrug ResistanceBiological AvailabilityAntineoplastic AgentsDrug resistanceCell LineMiceErlotinib HydrochlorideGefitinibIn vivomedicineAnimalsHumansOncology & CarcinogenesisNon-Small-Cell LungProtein Kinase InhibitorsLungCancerTumor microenvironmentTumorEndothelin-1business.industryCarcinomaLung CancerCancerEvaluation of treatments and therapeutic interventionsGefitinibmedicine.diseaseEndothelin 1Xenograft Model Antitumor AssaysErbB ReceptorsOncologyVasoconstriction5.1 Pharmaceuticals6.1 PharmaceuticalsCancer cellMutationCancer researchNeoplasmDevelopment of treatments and therapeutic interventionsbusinessmedicine.drug
researchProduct